Sinclair

Sinclair has an extensive commercial portfolio in medical aesthetics. Its flagship products include minimally invasive treatments such as Silhouette InstaLift®—an FDA-cleared device for mid-face tissue repositioning—and various injectable fillers and biostimulators. The company operates globally with direct presence and distributors in over 55 countries. It was acquired by Huadong Medicine Company Limited in November 2018 but continues to operate as a stand-alone entity under its own brand with an independent management team. The U.S. pipeline focuses on longer-duration, minimally invasive treatments that deliver natural-looking results and high patient satisfaction.